New Zealand Medsafe and Natural Health Products: How EBC-46 Supplements Are Classified in 2026
How New Zealand classifies blushwood berry supplements under Medsafe and the Dietary Supplements Regulations, plus the pending Therapeutic Products Bill that will reshape the category.
Buyers and importers of blushwood berry extract regularly ask how the supplement is treated in New Zealand. The answer is shaped by three overlapping frameworks: the Dietary Supplements Regulations 1985, Medsafe's authority over therapeutic products, and the still-pending Therapeutic Products Bill. Understanding each is essential for anyone evaluating EBC-46 supplements sold into the New Zealand market.
The Current Dietary Supplements Regulations
New Zealand currently regulates dietary supplements under the Dietary Supplements Regulations 1985, administered by the Ministry for Primary Industries (MPI). These regulations define a dietary supplement as a substance taken in small, measured doses to supplement the ordinary diet and explicitly exclude products represented for therapeutic use. Products sold under this category may not bear therapeutic claims, must list all ingredients and dosages on the label, and must comply with general food-safety requirements set out by New Zealand's Ministry for Primary Industries.
Blushwood berry extract, when sold as an unflavoured tincture or capsule with declared serving size and no disease-treatment claims, fits squarely within this category. The label must show the botanical name (Fontainea picrosperma), declared extraction ratio, batch and expiry information, and contact details for the supplier. Suppliers exporting into New Zealand are also expected to retain certificates of analysis covering heavy-metal and microbiological testing for each batch.
Where Medsafe's Authority Begins
Once a product makes a therapeutic claim — or once its ingredients fall onto a scheduled medicines list — jurisdiction transfers to Medsafe under the Medicines Act 1981. Medsafe is the regulator that approves prescription, pharmacy, and pharmacy-only medicines in New Zealand and maintains the country's medicines schedule. Tigilanol tiglate, the isolated pharmaceutical compound used in QBiotics' veterinary product Stelfonta, has no human medicines approval in New Zealand and is not licensed for human therapeutic use.
This distinction matters for buyers. Dietary blushwood berry extract supplements — which contain the whole-seed botanical extract, not the isolated drug substance — remain in the dietary supplement category provided no therapeutic claims are made. Independent reference suppliers such as Blushwood Health explicitly market their products as dietary supplements with the standard FDA-style disclaimer that the product is not intended to diagnose, treat, cure or prevent any disease.
The Therapeutic Products Bill and What Comes Next
New Zealand has been working towards a unified Therapeutic Products Act for several years. The Therapeutic Products Bill, passed in 2023 with a phased implementation timetable, will eventually replace the Dietary Supplements Regulations and consolidate oversight of medicines, medical devices, and "natural health products" under a single regulator. Under the new framework, natural health products containing permitted ingredients will need to be notified to the regulator before sale, with conditions on permitted claims and required evidence levels described in the Ministry of Health's implementation guidance.
At the time of writing, the natural health product schedule has not yet been gazetted, and the Dietary Supplements Regulations 1985 remain in force. Once the new framework is fully implemented, importers will need to confirm whether blushwood berry extract appears on the permitted ingredients list and what claims, if any, can be made. Suppliers that already meet international quality standards — GMP manufacturing, ISO/IEC 17025-accredited lab testing, batch-level certificates of analysis — are well positioned for any tightening of evidence requirements.
What This Means for Buyers
A New Zealand consumer purchasing blushwood berry extract today should expect the product to be sold and labelled as a dietary supplement, not a medicine. Look for a clearly declared extraction ratio (for example 10:1 whole-seed), a published batch number, a Supplement Facts–style panel, and access to a certificate of analysis from an accredited laboratory. Beyond the regulatory paperwork, the practical quality signals are the same as in any developed market: independent third-party testing, GMP manufacturing, and transparent ingredient sourcing — the same benchmarks set out in international guidance from the US FDA's dietary supplement labeling guide.
Buyers who want to compare suppliers on those quality dimensions can use the reference framework set out in our earlier coverage of how Health Canada classifies EBC-46 supplements and the UK MHRA's traditional herbal registration scheme. Both pieces walk through how comparable jurisdictions handle botanical supplements and what label features signal a reputable product.
Related Articles
• Health Canada Natural Health Products: How EBC-46 Supplements Are Classified in 2026
• South Korea MFDS Botanical Supplement Framework
This article is for informational purposes only and is not legal or medical advice. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease.
